CLSI EP17 Revision A2, 2012: Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline, CLSI規格 EP17, 2012: 臨床検査測定手順における検出能力の評価; 承認されたガイドライン

CLSI EP17 Revision A2, 2012(R2018): Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline (PDF/シングルユーザー)

産業規格・仕様書  >  CLSI 臨床・検査標準協会  > 




CLSI EP17 Revision A2, 2012(R2018): Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline (PDF/シングルユーザー)

35,530(税込)

数量

書名

CLSI EP17 Revision A2, 2012(R2018): Evaluation of Detection Capability for Clinical Laboratory
Measurement Procedures; Approved Guideline
CLSI規格 EP17, 2012(R2018): 臨床検査測定手順における検出能力の評価; 承認されたガイドライン
発行元 CLSI (Clinical and Laboratory Standards Institute)
発行年/月 2012年6月   
装丁 PDF / シングルユーザー
ページ数 80 ページ
発送予定 1-2営業日以内にお送りします
※当ウェブ・ショップに掲載のない規格につきましては、別途お問合せ下さいませ。

 

Description

This document provides guidelines for the evaluation and verification of detection capability claims of clinical laboratory measurement procedures (ie, limit of blank [LoB], limit of detection [LoD], and limit of quantitation [LoQ]), as well as for their proper use, documentation, and interpretation. This guidance is suitable both for commercial products as well as laboratory-developed tests. It is particularly important for measurement procedures for which the associated measurand’s medical decision level is low (ie, approaching zero).

The intended users of this guideline are manufacturers of in vitro diagnostic (IVD) reagents, regulatory bodies, and clinical laboratory personnel.